-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, it was reported that the Shenzhen Municipal Medical Insurance Bureau issued the "Notice on Implementing the Supporting Measures for Medical Insurance Related to the National Drug Centralized Procurement and Use Pilot Work (Draft for Comment)"
.
It is worth noting that during the circulation of the draft for comments, the price cuts of some foreign-funded pharmaceutical companies’ expired original drugs were also exposed at the same time
.
It is understood that the average price reduction of the original research drugs this time is 13.
25%.
Among them, the larger price reduction is GlaxoSmithKline's Weread, which is 33%; the smaller is Sanofi's Aventis Ambono, the price reduction is larger 8%
.
The analysis believes that this means that under the normalization of centralized procurement, not only generic drugs, but also the price reduction of original drug products has become a trend
.
In fact, judging from the development of the pharmaceutical industry in recent years under the continuous deepening of centralized procurement, since the "4+7" pilot program in 2018, the principle of "replacing price for quantity" in centralized procurement has attracted the participation of a large number of pharmaceutical companies In the context of the increase in the purchase of selected drugs, it has been driving the price reduction of unselected drugs, including unselected original drugs
.
It is reported that the current decline in some varieties has even reached 34%
.
In this regard, analysts believe that, on the whole, 4+7 has begun to bring the super-national treatment of original research drugs to the altar.
Pharmaceutical companies are expected to accelerate their rush to the market for original research drugs
.
For example, on February 18 this year, the website of the State Food and Drug Administration showed that the supplementary application for linezolid glucose injection of Chia Tai Tianqing Pharmaceutical Group was approved and reviewed
.
Data shows that in 2020, the sales of linezolid glucose injection in China's public medical institutions exceeded 1.
5 billion yuan.
After the launch of the Group's Linezolid Glucose Injection, it will have a greater impact on the Pfizer market
.
Prior to this, Chengdu Baiyu Pharmaceutical entered the administrative approval stage with its generic apixaban tablet, which was reported to be produced in Category 4, and is expected to become the company's second over-reviewed antithrombotic drug..
It is understood that apixaban is a potent, oral, reversible, direct and highly selective factor Xa active site inhibitor jointly developed by Pfizer and Bristol-Myers Squibb.
It is a new type of oral anticoagulant drug.
Prevention of venous thromboembolic events in adult patients undergoing elective hip or knee arthroplasty
.
According to data, the global sales of apixaban in 2021 have exceeded 10 billion US dollars
.
At present, in addition to Chengdu Baiyu Pharmaceutical, there are more than 20 companies whose apixaban tablets have passed or are deemed to have passed the consistency evaluation, including Qilu, Yangzijiang, CSPC, Kelun, and Haosen
.
In this regard, the industry expects that the market competition in this field will be very fierce in the future
.
In general, with the continuous improvement of the innovation strength of domestic pharmaceutical companies, the high-quality drug market will continue to develop rapidly.
It is expected to be seized by local enterprises, and a large number of imported original research drugs may also continue to join the ranks of active price reductions
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
It is worth noting that during the circulation of the draft for comments, the price cuts of some foreign-funded pharmaceutical companies’ expired original drugs were also exposed at the same time
.
It is understood that the average price reduction of the original research drugs this time is 13.
25%.
Among them, the larger price reduction is GlaxoSmithKline's Weread, which is 33%; the smaller is Sanofi's Aventis Ambono, the price reduction is larger 8%
.
The analysis believes that this means that under the normalization of centralized procurement, not only generic drugs, but also the price reduction of original drug products has become a trend
.
In fact, judging from the development of the pharmaceutical industry in recent years under the continuous deepening of centralized procurement, since the "4+7" pilot program in 2018, the principle of "replacing price for quantity" in centralized procurement has attracted the participation of a large number of pharmaceutical companies In the context of the increase in the purchase of selected drugs, it has been driving the price reduction of unselected drugs, including unselected original drugs
.
It is reported that the current decline in some varieties has even reached 34%
.
In this regard, analysts believe that, on the whole, 4+7 has begun to bring the super-national treatment of original research drugs to the altar.
Pharmaceutical companies are expected to accelerate their rush to the market for original research drugs
.
For example, on February 18 this year, the website of the State Food and Drug Administration showed that the supplementary application for linezolid glucose injection of Chia Tai Tianqing Pharmaceutical Group was approved and reviewed
.
Data shows that in 2020, the sales of linezolid glucose injection in China's public medical institutions exceeded 1.
5 billion yuan.
After the launch of the Group's Linezolid Glucose Injection, it will have a greater impact on the Pfizer market
.
Prior to this, Chengdu Baiyu Pharmaceutical entered the administrative approval stage with its generic apixaban tablet, which was reported to be produced in Category 4, and is expected to become the company's second over-reviewed antithrombotic drug..
It is understood that apixaban is a potent, oral, reversible, direct and highly selective factor Xa active site inhibitor jointly developed by Pfizer and Bristol-Myers Squibb.
It is a new type of oral anticoagulant drug.
Prevention of venous thromboembolic events in adult patients undergoing elective hip or knee arthroplasty
.
According to data, the global sales of apixaban in 2021 have exceeded 10 billion US dollars
.
At present, in addition to Chengdu Baiyu Pharmaceutical, there are more than 20 companies whose apixaban tablets have passed or are deemed to have passed the consistency evaluation, including Qilu, Yangzijiang, CSPC, Kelun, and Haosen
.
In this regard, the industry expects that the market competition in this field will be very fierce in the future
.
In general, with the continuous improvement of the innovation strength of domestic pharmaceutical companies, the high-quality drug market will continue to develop rapidly.
It is expected to be seized by local enterprises, and a large number of imported original research drugs may also continue to join the ranks of active price reductions
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
